CHRS - Coherus BioSciences Inc. (CHRS) Q1 2024 Earnings Call Transcript

2024-05-10 00:07:07 ET

Coherus BioSciences, Inc. (CHRS)

Q1 2024 Earnings Conference Call

May 09, 2024 05:00 PM ET

Company Participants

Jamie Taylor - Head of Investor Relations

Denny Lanfear - Chief Executive Officer

Paul Reider - Chief Commercial Officer

Rosh Dias - Chief Medical Officer

Theresa LaVallee - Chief Development Officer

Bryan McMichael - Interim Chief Financial Officer

Conference Call Participants

Michael Nedelcovych - TD Cowen

Douglas Tsao - H.C. Wainwright

Colleen Kusy - Baird

Presentation

Operator

Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Coherus BioSciences, Inc. First Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any backward notes. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Jamie Taylor, Head of Investor Relations. Please go ahead.

Jamie Taylor

Thank you, operator. Good afternoon, and welcome to Coherus BioSciences first quarter 2024 earnings conference call. Joining me today to discuss our results are Denny Lanfear, Chief Executive Officer of Coherus; Bryan McMichael, our Interim Chief Financial Officer; Paul Reider, our Chief Commercial Officer; Rosh Dias, Chief Medical Officer; and Theresa LaVallee, our Chief Development Officer.

Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, the following: Our ability to advance our pipeline, projections of future growth, revenue, expenses, headcount, and debt levels. All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements.

These statements are not guarantees to future performance and are subject to substantial risks and uncertainties, including risks and uncertainties inherent in the clinical drug development process that are discussed in our press release that we issued today, as well as the documents that we file with the SEC. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statement.

And now, I'll turn the call over to Denny.

Denny Lanfear

Thank you, Jamie. Good afternoon, everyone, and thank you for joining us on our call today. As we open the call, let me emphasize two things: First, the strength of our first quarter results; and secondly, the strategic initiatives, we are successfully executing to position our company for long-term success....

For further details see: